We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

AZRG:TASEAzrieli Group Ltd. Analysis

Data as of 2026-06-10 - not real-time

$137.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Azrieli Group Ltd. (AZRG) is trading at the exact 20‑day and 50‑day SMA of $137, with price flat on both support and resistance. The RSI of 99.99 signals an extreme overbought condition, while the MACD shows a bearish crossover (negative histogram), suggesting short‑term downside pressure. Despite the technical weakness, the stock trades at a PE of 25.9, well below the industry average of 33.1, and a price‑to‑book of 0.67, indicating a valuation cushion. The dividend yield of 1.66% with a payout ratio around 42% appears sustainable, even though free cash flow is currently negative and debt‑to‑equity is high at ~110%.
The recent earnings call highlighted a rise in net income and strategic expansion into data centers and senior housing, which could fuel medium‑ to long‑term earnings growth. Combined with a moderate ROE of 7.8% and strong profit margins, the fundamentals support a blend of growth and value. However, low trading volume and a flat price range increase liquidity risk, and the high leverage warrants caution. Overall, the stock looks undervalued from a valuation standpoint but faces short‑term technical headwinds.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • RSI at extreme overbought levels
  • Bearish MACD crossover
  • Price trapped at flat support/resistance with low volume

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Strategic investments in data centers and senior housing
  • Undervalued valuation multiples (PE below industry, PB < 1)
  • Sustainable dividend yield

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Long‑term growth drivers from mixed‑use property portfolio
  • Consistent dividend payments
  • Fundamental upside from earnings growth despite current cash flow constraints

Key Metrics & Analysis

Financial Health

Revenue Growth18.90%
Profit Margin48.31%
P/E Ratio25.9
ROE7.80%
ROA2.05%
Debt/Equity109.97
P/B Ratio0.7
Free Cash Flow$-455124992
Industry P/E33.1

Technical Analysis

TrendNeutral
RSI100.0
Support$137.00
Resistance$137.00
MA 20$137.00
MA 50$137.00
MA 200$116.16
MACDBearish
VolumeStable
Fear & Greed Index85.95

Valuation

GradeUndervalued
TypeBlend
Dividend Yield1.66%

Risk Assessment

Beta-0.00
0
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.